MEOBF - bluebird's European MAA And Other News: The Good Bad And Ugly Of Biopharma
- bluebird bio announces European acceptance of eli-cel gene therapy.
- Arena Pharmaceuticals completes enrollment for CAPTIVATE trial.
- Mesoblast suffers a setback as FDA rejects cell therapy application.
For further details see:
bluebird's European MAA, And Other News: The Good, Bad And Ugly Of Biopharma